Skip to content
ppharmaranks
Menu
Class IIOngoing

Amlodipine and Olmesartan Medoxomil Tablets recall

FDA recall D-0576-2025 · initiated Jul 21, 2025

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Aug 20, 2025How we research

Ascend Laboratories, LLC recalled Amlodipine and Olmesartan Medoxomil Tablets in Jul 2025 — an FDA Class II recall (D-0576-2025) because Failed Dissolution Specifications: low dissolution results.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Failed Dissolution Specifications: low dissolution results

Wrong strength, or it did not keep

The product did not contain what the label promised, or stopped meeting specification before its expiry date. Under-strength medicine can mean an untreated condition.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot 23121560, Exp 4/30/2026

Quantity recalled: 8,568 bottles

Details

Product
Amlodipine and Olmesartan Medoxomil Tablets, 5 mg/ 40 mg, 30-count bottle, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA; Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-501-30
Recalling company
Ascend Laboratories, Ltd
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide in the USA
Initiated
Jul 21, 2025
FDA report date
Aug 20, 2025
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Amlodipine and Olmesartan Medoxomil Tablets recalled?
Ascend Laboratories, LLC recalled Amlodipine and Olmesartan Medoxomil Tablets in Jul 2025 — an FDA Class II recall (D-0576-2025) because Failed Dissolution Specifications: low dissolution results. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Amlodipine and Olmesartan Medoxomil Tablets recalled?
Per the FDA enforcement record, the reason for recall D-0576-2025 was: Failed Dissolution Specifications: low dissolution results
Is a recalled Amlodipine and Olmesartan Medoxomil Tablets dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Amlodipine and Olmesartan Medoxomil Tablets are affected?
Distributed: Nationwide in the USA. The recall covers these lots — Lot 23121560, Exp 4/30/2026. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0576-2025.

Source: openFDA Drug Enforcement record D-0576-2025

← All drug recalls